AT340892B - Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen - Google Patents

Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen

Info

Publication number
AT340892B
AT340892B AT975075A AT975075A AT340892B AT 340892 B AT340892 B AT 340892B AT 975075 A AT975075 A AT 975075A AT 975075 A AT975075 A AT 975075A AT 340892 B AT340892 B AT 340892B
Authority
AT
Austria
Prior art keywords
cycloalkanethic
aminomethyl
esters
acids
salt
Prior art date
Application number
AT975075A
Other languages
English (en)
Other versions
ATA975075A (de
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5934284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT340892(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ATA975075A publication Critical patent/ATA975075A/de
Application granted granted Critical
Publication of AT340892B publication Critical patent/AT340892B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT975075A 1974-12-21 1975-12-22 Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen AT340892B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2460891A DE2460891C2 (de) 1974-12-21 1974-12-21 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
ATA975075A ATA975075A (de) 1977-05-15
AT340892B true AT340892B (de) 1978-01-10

Family

ID=5934284

Family Applications (1)

Application Number Title Priority Date Filing Date
AT975075A AT340892B (de) 1974-12-21 1975-12-22 Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen

Country Status (16)

Country Link
US (1) US4024175A (de)
JP (1) JPS5324064B2 (de)
AT (1) AT340892B (de)
BE (1) BE836835A (de)
CA (1) CA1052811A (de)
CH (3) CH612665A5 (de)
DE (1) DE2460891C2 (de)
DK (1) DK147706C (de)
ES (1) ES443723A1 (de)
FI (1) FI62282C (de)
FR (1) FR2294697A1 (de)
GB (1) GB1465229A (de)
IE (1) IE42382B1 (de)
LU (1) LU74058A1 (de)
NL (1) NL181006C (de)
SE (1) SE423385B (de)

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
JPS5776189U (de) * 1980-10-28 1982-05-11
JPS6152583U (de) * 1984-09-11 1986-04-09
JPS61139881U (de) * 1985-02-21 1986-08-29
US4876279A (en) * 1986-05-05 1989-10-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
AU633612B2 (en) * 1989-08-25 1993-02-04 Warner-Lambert Company Improved process for cyclic amino acid anticonvulsant compounds
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5260467A (en) * 1989-11-16 1993-11-09 Pfizer Inc. Glutaric acid derivatives and preparation thereof
GB8925933D0 (en) * 1989-11-16 1990-01-04 Pfizer Ltd Glutaric acid derivatives and preparation thereof
FI905584L (fi) * 1989-11-16 1991-05-17 Lonza Ag Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
US5157138A (en) * 1989-11-16 1992-10-20 Pfizer, Inc. Glutaric acid derivatives and preparation thereof
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
PL328432A1 (en) * 1996-02-07 1999-02-01 Warner Lambert Co Novel cyclic amino acids as pharmaceutic agents
WO1997033859A1 (en) * 1996-03-14 1997-09-18 Warner-Lambert Company Novel bridged cyclic amino acids as pharmaceutical agents
WO1997033858A1 (en) * 1996-03-14 1997-09-18 Warner-Lambert Company Novel substituted cyclic amino acids as pharmaceutical agents
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
CA2263663C (en) * 1996-10-23 2006-05-30 Justin Stephen Bryans Substituted gamma aminobutyric acids as pharmaceutical agents
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6255526B1 (en) 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
WO1999008667A2 (en) 1997-08-19 1999-02-25 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
JP3782935B2 (ja) * 1997-09-08 2006-06-07 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗癲癇化合物を含有する鎮痛剤組成物およびその使用方法
US6294690B1 (en) 1997-10-07 2001-09-25 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
EP1032555B1 (de) * 1997-10-27 2006-04-12 Warner-Lambert Company Llc Zyklische aminosäuren und deren derivate als arzneimittel
US6984659B2 (en) * 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
CN1279667A (zh) 1997-12-16 2001-01-10 沃尼尔·朗伯公司 4(3)取代－4(3)－氨基甲基－(硫代)吡喃(噻喃)或－哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
ATE260904T1 (de) 1997-12-16 2004-03-15 Warner Lambert Co ((cyclo)alkyl substituierte)-.gamma.- aminobuttersäure derivate (=gaba analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen
ES2227896T3 (es) * 1997-12-16 2005-04-01 Warner-Lambert Company Llc Derivados de 1-aminometil-cicloalcanos sustituidos en 1 (=analogos de gabapentina), su preparacion y su uso en el tratamiento de trastornos neurologicos.
WO1999037296A1 (en) * 1998-01-23 1999-07-29 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
EP0974351A3 (de) * 1998-04-24 2000-12-13 Jouveinal Arzneimittel zur Vorbeugung und Behandlung von Magendarmschäden
EP1077692B1 (de) 1998-05-15 2004-07-28 Warner-Lambert Company LLC Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
KR100669280B1 (ko) * 1998-05-15 2007-01-17 워너-램버트 캄파니 엘엘씨 감마-아미노부티르산 유도체 포함 고상 조성물 및 그의제조 방법
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
US6316638B1 (en) 1998-05-26 2001-11-13 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
ITMI981535A1 (it) * 1998-07-03 2000-01-03 Zambon Spa Processo per la preparazione di gabapentina
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
IT1311984B1 (it) 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
EP1169060B1 (de) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
MXPA01011059A (es) * 1999-05-28 2002-06-04 Warner Lambert Co Analogos gaba 3-heteroarilalquilo sustituidos.
US6710190B1 (en) * 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
RS20090257A (sr) * 1999-06-10 2010-03-02 Warner-Lambert Company Mono-i-disupstituisane 3-propil gama-aminobuterne kiseline
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
EP1384473A1 (de) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stabiles Gabapentin das mehr als 20 ppm Chlor enthält
PT1289364E (pt) 2000-06-16 2004-04-30 Teva Pharma Gabapentina estavel contendo mais do que 20 ppm de iao cloreto
KR20060123782A (ko) * 2000-06-16 2006-12-04 테바 파마슈티컬 인더스트리즈 리미티드 제어 범위 내의 ｐｈ를 갖는 안정한 가바펜틴
ES2300332T3 (es) * 2000-06-26 2008-06-16 Warner-Lambert Company Llc Analogos de gabapentina para trastornos del sueño.
GB2364049A (en) * 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
DK1317426T3 (da) * 2000-09-14 2006-01-09 Gruenenthal Gmbh Betal-thio-aminosyrer
US6900192B2 (en) * 2000-10-06 2005-05-31 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
IT1319234B1 (it) * 2000-10-23 2003-09-26 Zambon Spa Processo di preparazione di gabapentina.
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
HUP0303352A3 (en) * 2000-11-02 2005-04-28 Teva Pharma Improved process for production of gabapentin intermediate
JP2004514700A (ja) * 2000-11-30 2004-05-20 ファイザー・プロダクツ・インク Ｇａｂａアゴニスト及びアルドース還元酵素阻害剤の組み合わせ
OA12534A (en) * 2000-11-30 2006-06-05 Pfizer Prod Inc Combination of GABA agonists and sorbitol dehydrogenase inhibitors.
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
JP2004524339A (ja) * 2001-03-16 2004-08-12 ソルケム イタリアーナ エス．ピー．エイ． 環状アミノ酸の調製方法
ITMI20011132A1 (it) 2001-05-29 2002-11-29 Procos Spa Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
MXPA03011566A (es) 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JP2005501013A (ja) * 2001-06-11 2005-01-13 ゼノポート，インコーポレイテッド Ｇａｂａ類似体の全身濃度が持続するアミノ酸コンジュゲート
IL144066A0 (en) * 2001-06-28 2002-04-21 Bromine Compounds Ltd Process for the preparation of 1,1-cyclohexane diacetic monoamide
ITMI20011772A1 (it) 2001-08-10 2003-02-10 A M S A Anonima Materie Sint E Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
US8084447B2 (en) * 2001-09-03 2011-12-27 Newron Pharmaceuticals S.P.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
EP1469841A1 (de) * 2002-01-31 2004-10-27 Warner-Lambert Company Alpha 2 delta ligands zur behandlung von ohrensausen
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7026351B2 (en) 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
AU2003262383A1 (en) * 2002-04-16 2003-11-03 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
EP1549323A2 (de) * 2002-05-07 2005-07-06 A & D Bioscience, Inc. Konjugate mit einem wirkstoff für das zentrale nervensystem
US7183259B2 (en) * 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
CA2488566A1 (en) * 2002-06-27 2004-01-08 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
US7053122B2 (en) * 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US20040092591A1 (en) * 2002-08-15 2004-05-13 Blakemore David Clive Therapeutic use of fused bicyclic or tricyclic amino acids
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
ITMI20022071A1 (it) * 2002-10-01 2004-04-02 Erregierre Spa Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
WO2004046084A1 (en) * 2002-11-18 2004-06-03 Nicholas Piramal India Limited Improved process for preparation of gabapentin
EP1599446B1 (de) * 2002-11-20 2009-08-12 Hikal Ltd. Verbessertes verfahren zur zubereitung von gabalactam
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
CA2508297A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
CN101862317A (zh) * 2002-12-13 2010-10-20 沃尼尔·朗伯有限责任公司 用于治疗纤维肌痛和其它疾病的普加巴林衍生物
WO2004054564A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
KR100743800B1 (ko) * 2003-01-22 2007-07-30 워너-램버트 캄파니 엘엘씨 사이클로프로필 베타-아미노산 유도체
MXPA05009504A (es) * 2003-03-07 2005-10-18 Warner Lambert Co Derivados de (-aminoacidos sustituidos con tetrazol y oxadiazolona.
DE602004017166D1 (de) * 2003-03-25 2008-11-27 Kiel Lab Inc Gabapentintannat in flüssigen und/oder halbfesten dosierformen
WO2004093827A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in solid dosage forms and methods of use
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
AU2004227995B2 (en) * 2003-03-31 2010-06-03 Xenoport, Inc. Treating or preventing hot flashes using prodrugs of GABA analogs
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
ITMI20030825A1 (it) * 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione di gabapentin esente da
EP1615875A2 (de) * 2003-04-21 2006-01-18 Matrix Laboratories Limited Verfahren zur herstellung von gabapentin form-ii
MXPA05012317A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
JP2006527595A (ja) * 2003-06-19 2006-12-07 ファイザー・プロダクツ・インク １−シアノシクロヘキサンアセティックアシッドの生体触媒による調製
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
MXPA06002731A (es) * 2003-09-11 2006-06-05 Xenoport Inc Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
RU2006107534A (ru) * 2003-09-12 2007-09-20 Уорнер-Ламберт Компани Ллс (Us) Комбинация, включающая альфа-2-дельта-лиганд анд и ssri и/или snri, для лечения депрессии и тревожного расстройства
BRPI0414343A (pt) * 2003-09-12 2006-11-07 Pfizer combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina
AU2004274002B2 (en) * 2003-09-17 2011-04-28 Arbor Pharmaceuticals, Llc Treating or preventing restless legs syndrome using prodrugs of GABA analogs
SI1677767T1 (sl) 2003-10-14 2011-11-30 Xenoport Inc Kristalinična oblika analoga gama-aminomaslene kisline
ITMI20032165A1 (it) * 2003-11-11 2005-05-12 Zambon Spa Processo di preparazione di gabapentina
JP5646126B2 (ja) 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
WO2005087709A1 (en) * 2004-03-17 2005-09-22 Hikal Limited 4-t-butylgabapentin and its synthesis
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
EP1737473A4 (de) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Lithium-kombinationen und relevante verwendungen
RU2006143659A (ru) * 2004-06-09 2008-06-20 Пфайзер Инк. (Uпфайзер Инк. (Us)S) Применение ребоксетина для лечения боли
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0419849D0 (en) * 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
CA2577408C (en) * 2004-09-10 2013-07-09 Elena Barbanti Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
JP2008518971A (ja) * 2004-11-04 2008-06-05 ゼノポート，インコーポレイティド ガバペンチンプロドラッグ持続放出経口薬剤
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
BRPI0616263A2 (pt) * 2005-09-23 2011-06-14 Janssen Pharmaceutica Nv moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
PL1931335T3 (pl) * 2005-09-23 2010-07-30 Janssen Pharmaceutica Nv Modulatory heksahydrocyklooktylopirazolokannabinoidowe
CN101312726A (zh) * 2005-09-23 2008-11-26 詹森药业有限公司 六氢-环庚三烯并吡唑大麻素调节剂
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP1979593B1 (de) * 2006-02-03 2017-12-06 Rolls-Royce Corporation Gasturbinenantriebsstoffsystem mit treibstoffmessendem ventil
EP1820502A1 (de) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Wirkstoffzusammensetzungen enthaltend Azolycarbinolderivate
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
EP1993529A1 (de) * 2006-03-06 2008-11-26 Pfizer Products Inc. Alpha-2-delta-liganden für nicht-restorativen schlaf
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (de) 2006-05-09 2009-02-25 Braincells, Inc. 5-ht-rezeptor-vermittelte neurogenese
US7442834B2 (en) * 2006-06-12 2008-10-28 Zhejiang Chiral Medicine Chemicals Co., Ltd. Process suitable for industrial scale production of gabapentin
EP2038249B1 (de) * 2006-06-30 2013-09-11 ZaCh System S.p.A. Verfahren zur herstellung von gabapentin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080161393A1 (en) * 2006-12-08 2008-07-03 Barrett Ronald W Use of prodrugs of GABA analogs for treating disease
AU2007338367B2 (en) 2006-12-22 2010-05-20 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with alpha2delta ligands and NSAIDs
JP2010521453A (ja) * 2007-03-15 2010-06-24 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 新規プロドラッグ
TW200908957A (en) * 2007-06-15 2009-03-01 Xenoport Inc Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090062392A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched gabapentin
TW200936123A (en) * 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
EP2250148B1 (de) 2008-01-25 2016-08-17 XenoPort, Inc. Kristalline form von kalziumsalzen von (3s)-aminomethyl-5-methylhexansäuren und anwendungsverfahren
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
EP2116539A1 (de) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101810246B1 (ko) * 2008-10-08 2017-12-18 엑스진 파마슈티컬 인크. Ｇａｂａ 접합체 및 그의 사용 방법
EP2400989B1 (de) 2009-02-24 2016-08-10 Nektar Therapeutics Gabapentin-peg konjugate
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
EP2353591A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
EP2368872A1 (de) 2010-03-25 2011-09-28 Serichim S.r.l. Verfahren zur Herstellung von Gabapentin
EP2388005A1 (de) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
WO2011151708A1 (en) 2010-06-01 2011-12-08 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
US8431739B2 (en) 2010-06-14 2013-04-30 Divi's Laboratories, Ltd. Process for the preparation of gabapentin
PL2599487T3 (pl) 2010-07-30 2015-09-30 Toray Industries Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu
EP2415471A1 (de) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
JP2013216580A (ja) * 2010-08-06 2013-10-24 Kyorin Pharmaceutical Co Ltd ビシクロ［２．２．２］オクチルアミン誘導体の製造方法
EP2524694A1 (de) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
EP2530072A1 (de) 2011-06-03 2012-12-05 Lacer, S.A. Neue Verbindungen, deren Synthese und Verwendung bei der Schmerzbehandlung
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina
WO2015064453A1 (ja) 2013-11-01 2015-05-07 株式会社糖鎖工学研究所 チオール基を有するｄ－体またはｌ－体アミノ酸誘導体の製造方法
CN105873578A (zh) 2013-12-17 2016-08-17 埃斯蒂维实验室股份有限公司 血清素－去甲肾上腺素再摄取抑制剂(SNRIs)和σ受体配体组合物
EP3082790A1 (de) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. Kombinationen mit gabapentinoiden und sigma-rezeptorliganden
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
EP3554490B1 (de) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmazeutische kombination mit einem calciumkanalblocker vom typ t
MX384760B (es) 2018-07-04 2025-03-14 Federico Amezcua Amezcua Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
US10399926B1 (en) 2018-08-01 2019-09-03 Divi's Laboratories Ltd. Process for the preparation of gabapentin
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
AU2020370758B2 (en) 2019-10-25 2025-08-14 Kyoto University Preventative or therapeutic agent for tauopathy
KR20220163384A (ko) 2020-03-04 2022-12-09 플레오파마, 엘.엘.씨. 칸나비스 사용 장애를 치료하고 칸나비노이드 금단을 완화하기 위한 방법 및 조성물
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
GB2625579A (en) 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Also Published As

Publication number Publication date
JPS5324064B2 (de) 1978-07-18
JPS5188940A (de) 1976-08-04
ES443723A1 (es) 1977-04-16
DE2460891C2 (de) 1982-09-23
NL181006C (nl) 1987-06-01
NL7514900A (nl) 1976-06-23
IE42382B1 (en) 1980-07-30
DK147706B (da) 1984-11-19
FR2294697A1 (fr) 1976-07-16
CA1052811A (en) 1979-04-17
US4024175A (en) 1977-05-17
CH612665A5 (de) 1979-08-15
SE7514442L (sv) 1976-06-22
IE42382L (en) 1976-06-21
FI62282B (fi) 1982-08-31
DK581475A (da) 1976-01-22
GB1465229A (en) 1977-02-23
NL181006B (nl) 1987-01-02
FR2294697B1 (de) 1978-07-28
FI753613A7 (de) 1976-06-22
CH612666A5 (de) 1979-08-15
CH612664A5 (de) 1979-08-15
LU74058A1 (de) 1976-07-20
BE836835A (fr) 1976-06-18
ATA975075A (de) 1977-05-15
SE423385B (sv) 1982-05-03
FI62282C (fi) 1982-12-10
DK147706C (da) 1985-05-13
AU8774175A (en) 1977-06-23
DE2460891A1 (de) 1976-07-01

Similar Documents

Publication Publication Date Title
AT340892B (de) Verfahren zur herstellung von neuen 1-aminomethyl-1-cycloalkanessigsauren und deren estern sowie salzen
AT341506B (de) Verfahren zur herstellung von neuen substituierten phenylessigsauren und ihren estern
ATA693675A (de) Verfahren zur herstellung von neuen fusidinsaurederivaten, sowie deren salzen und estern
AT328449B (de) Verfahren zur herstellung von neuen chinolincarbonsaure- (2) -verbindungen und deren estern und salzen
AT327903B (de) Verfahren zur herstellung von neuen estern und amiden von pyridin-2-carbonsauren
AT326148B (de) Verfahren zur herstellung von neuen carboxyphenylalkylphosphinsäuren sowie deren estern
AT329181B (de) Verfahren zur herstellung von neuen 7-acylamido-3-fluor-3-cephem-4-carbonsaureestern und -sauren
AT299909B (de) Verfahren zur Herstellung von neuen Sulfamylanthranilsäuren sowie deren Salzen und Estern
AT335439B (de) Verfahren zur herstellung von neuen phenoxyalkylcarbonsauren und von deren estern
AT326629B (de) Verfahren zur herstellung von neuen 5-sulfamoylbenzoesäuren, sowie von deren salzen und estern
ATA953474A (de) Verfahren zur herstellung von neuen acylaminocephemcarbonsauren und von deren salzen und estern
AT344161B (de) Verfahren zur herstellung von neuen phenoxyalkancarbonsaeureamiden von thiazolidincarbonsaeuren und ihren salzen
ATA638275A (de) Verfahren zur herstellung von neuen cinnolin-3-yl-carbonsauren und von deren salzen
AT308733B (de) Verfahren zur Herstellung von neuen 9,10-Dihydro-9,10-dioxo-anthracen-2-carbonsäuren sowie deren Salzen und Estern
AT341505B (de) Verfahren zur herstellung von neuen phenylalkansauren, deren estern oder amiden und deren salzen
AT337678B (de) Verfahren zur herstellung von neuen indanylessigsauren und deren metallsalzen
ATA424575A (de) Verfahren zur herstellung von neuen aminoalkylphenoxyalkansaeuren, deren estern und salzen
AT335601B (de) Verfahren zur herstellung von 7-amino-3-cephem-4-carbonsauren und deren estern und salzen
ATA902277A (de) Verfahren zur herstellung von neuen estern von phenylaethylaminderivaten und von deren saeure- additionssalzen
ATA125278A (de) Verfahren zur herstellung von neuen amino- alkylphenoxyalkansaeuren, deren estern und salzen
AT320857B (de) Verfahren zur Herstellung von neuen α-Carboxy-2-thienylmethylpenicillinen und α-Carboxy-2-thienylmethylcephalosporinen sowie deren Estern und basischen Salzen
ATA125178A (de) Verfahren zur herstellung von neuen amino- alkylphenoxyalkansaeuren und deren estern und salzen
AT326105B (de) Verfahren zur herstellung von neuen 5-sulfamoylbenzoesauren, sowie von deren salzen und estern
ATA549776A (de) Verfahren zur herstellung von neuen 1-amino-alkyl-2-aryl-cyclohexanolen und deren estern
ATA995774A (de) Verfahren zur herstellung von neuen diphenoxyessigsauren und deren estern sowie deren salzen

Legal Events

Date Code Title Description
SZA Application filed for a certificate of protection

Free format text: SZ98/94, 941220

ELA Expired due to lapse of time
EZF Grant of a certificate of protection

Free format text: SZ 98/94, 941220, EXPIRES:20000515